Literature DB >> 27226559

Neutralization of RANTES and Eotaxin Prevents the Loss of Dopaminergic Neurons in a Mouse Model of Parkinson Disease.

Goutam Chandra1, Suresh B Rangasamy1, Avik Roy1, Jeffrey H Kordower1, Kalipada Pahan2.   

Abstract

Parkinson disease (PD) is second only to Alzheimer disease as the most common human neurodegenerative disorder. Despite intense investigation, no interdictive therapy is available for PD. Recent studies indicate that both innate and adaptive immune processes are active in PD. Accordingly, we found a rapid increase in RANTES (regulated on activation normal T cell expressed and secreted) and eotaxin, chemokines that are involved in T cell trafficking, in vivo in the substantia nigra pars compacta and the serum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-intoxicated mice. RANTES and eotaxin were also up-regulated in the substantia nigra pars compacta of post-mortem PD brains as compared with age-matched controls. Therefore, we investigated whether neutralization of RANTES and eotaxin could protect against nigrostriatal degeneration in MPTP-intoxicated mice. Interestingly, after peripheral administration, functional blocking antibodies against RANTES and eotaxin reduced the infiltration of CD4(+) and CD8(+) T cells into the nigra, attenuated nigral expression of proinflammatory molecules, and suppressed nigral activation of glial cells. These findings paralleled dopaminergic neuronal protection, normalized striatal neurotransmitters, and improved motor functions in MPTP-intoxicated mice. Therefore, we conclude that attenuation of the chemokine-dependent adaptive immune response may be of therapeutic benefit for PD patients.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Parkinson disease; T-cell; animal model; glial cell; neurodegeneration; neuroinflammation

Mesh:

Substances:

Year:  2016        PMID: 27226559      PMCID: PMC4946939          DOI: 10.1074/jbc.M116.714824

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  44 in total

1.  Gender-specific expression of beta1 integrin of VLA-4 in myelin basic protein-primed T cells: implications for gender bias in multiple sclerosis.

Authors:  Saurav Brahmachari; Kalipada Pahan
Journal:  J Immunol       Date:  2010-05-05       Impact factor: 5.422

2.  Systemic inflammation induces acute behavioral and cognitive changes and accelerates neurodegenerative disease.

Authors:  Colm Cunningham; Suzanne Campion; Katie Lunnon; Carol L Murray; Jack F C Woods; Robert M J Deacon; J Nicholas P Rawlins; V Hugh Perry
Journal:  Biol Psychiatry       Date:  2008-09-18       Impact factor: 13.382

3.  Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease.

Authors:  Anamitra Ghosh; Avik Roy; Joanna Matras; Saurav Brahmachari; Howard E Gendelman; Kalipada Pahan
Journal:  J Neurosci       Date:  2009-10-28       Impact factor: 6.167

4.  Reactive oxygen species up-regulate CD11b in microglia via nitric oxide: Implications for neurodegenerative diseases.

Authors:  Avik Roy; Arundhati Jana; Kavitha Yatish; Matthew B Freidt; Yiu K Fung; Jeffrey A Martinson; Kalipada Pahan
Journal:  Free Radic Biol Med       Date:  2008-06-06       Impact factor: 7.376

5.  Sodium benzoate, a metabolite of cinnamon and a food additive, reduces microglial and astroglial inflammatory responses.

Authors:  Saurav Brahmachari; Arundhati Jana; Kalipada Pahan
Journal:  J Immunol       Date:  2009-10-07       Impact factor: 5.422

6.  Up-regulation of microglial CD11b expression by nitric oxide.

Authors:  Avik Roy; Yiu K Fung; Xiaojuan Liu; Kalipada Pahan
Journal:  J Biol Chem       Date:  2006-03-20       Impact factor: 5.157

Review 7.  A Perspective on Roles Played by Innate and Adaptive Immunity in the Pathobiology of Neurodegenerative Disorders.

Authors:  Howard E Gendelman; R Lee Mosley
Journal:  J Neuroimmune Pharmacol       Date:  2015-10-31       Impact factor: 4.147

8.  Systemic challenge with the TLR3 agonist poly I:C induces amplified IFNalpha/beta and IL-1beta responses in the diseased brain and exacerbates chronic neurodegeneration.

Authors:  Robert Field; Suzanne Campion; Colleen Warren; Carol Murray; Colm Cunningham
Journal:  Brain Behav Immun       Date:  2010-04-23       Impact factor: 7.217

9.  Evidence for a role of adaptive immune response in the disease pathogenesis of the MPTP mouse model of Parkinson's disease.

Authors:  Heather L Martin; Matteo Santoro; Sarah Mustafa; Gernot Riedel; John V Forrester; Peter Teismann
Journal:  Glia       Date:  2015-10-29       Impact factor: 7.452

10.  Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons.

Authors:  Eric J Benner; Rebecca Banerjee; Ashley D Reynolds; Simon Sherman; Vladimir M Pisarev; Vladislav Tsiperson; Craig Nemachek; Pawel Ciborowski; Serge Przedborski; R Lee Mosley; Howard E Gendelman
Journal:  PLoS One       Date:  2008-01-02       Impact factor: 3.240

View more
  21 in total

1.  Low-Dose Maraviroc, an Antiretroviral Drug, Attenuates the Infiltration of T Cells into the Central Nervous System and Protects the Nigrostriatum in Hemiparkinsonian Monkeys.

Authors:  Susanta Mondal; Suresh B Rangasamy; Avik Roy; Sridevi Dasarathy; Jeffrey H Kordower; Kalipada Pahan
Journal:  J Immunol       Date:  2019-05-01       Impact factor: 5.422

2.  Induction of Adaptive Immunity Leads to Nigrostriatal Disease Progression in MPTP Mouse Model of Parkinson's Disease.

Authors:  Goutam Chandra; Avik Roy; Suresh B Rangasamy; Kalipada Pahan
Journal:  J Immunol       Date:  2017-04-26       Impact factor: 5.422

3.  Low Levels of Prohibitin in Substantia Nigra Makes Dopaminergic Neurons Vulnerable in Parkinson's Disease.

Authors:  Debashis Dutta; Nilufar Ali; Emili Banerjee; Raghavendra Singh; Amit Naskar; Ramesh Kumar Paidi; Kochupurackal P Mohanakumar
Journal:  Mol Neurobiol       Date:  2017-01-06       Impact factor: 5.590

4.  Slowing Parkinson's Disease Progression with Vaccination and Other Immunotherapies.

Authors:  Dhanya Vijayakumar; Joseph Jankovic
Journal:  CNS Drugs       Date:  2022-02-25       Impact factor: 5.749

Review 5.  Neuroinflammation in Parkinson's Disease - Putative Pathomechanisms and Targets for Disease-Modification.

Authors:  Alexander Grotemeyer; Rhonda Leah McFleder; Jingjing Wu; Jörg Wischhusen; Chi Wang Ip
Journal:  Front Immunol       Date:  2022-05-18       Impact factor: 8.786

6.  Thymoquinone increases the expression of neuroprotective proteins while decreasing the expression of pro-inflammatory cytokines and the gene expression NFκB pathway signaling targets in LPS/IFNγ -activated BV-2 microglia cells.

Authors:  Makini K Cobourne-Duval; Equar Taka; Patricia Mendonca; Karam F A Soliman
Journal:  J Neuroimmunol       Date:  2018-05-04       Impact factor: 3.478

7.  Editor's Highlight: Nlrp3 Is Required for Inflammatory Changes and Nigral Cell Loss Resulting From Chronic Intragastric Rotenone Exposure in Mice.

Authors:  Eileen M Martinez; Alison L Young; Yash R Patankar; Brent L Berwin; Li Wang; Katharine M von Herrmann; Jaclyn M Weier; Matthew C Havrda
Journal:  Toxicol Sci       Date:  2017-09-01       Impact factor: 4.849

Review 8.  Emerging targets for the diagnosis of Parkinson's disease: examination of systemic biomarkers.

Authors:  Lara Cheslow; Adam E Snook; Scott A Waldman
Journal:  Biomark Med       Date:  2021-05-14       Impact factor: 2.498

Review 9.  Parkinson disease and the immune system - associations, mechanisms and therapeutics.

Authors:  Eng-King Tan; Yin-Xia Chao; Andrew West; Ling-Ling Chan; Werner Poewe; Joseph Jankovic
Journal:  Nat Rev Neurol       Date:  2020-04-24       Impact factor: 42.937

10.  Reduction of Lewy Body Pathology by Oral Cinnamon.

Authors:  Sumita Raha; Debashis Dutta; Avik Roy; Kalipada Pahan
Journal:  J Neuroimmune Pharmacol       Date:  2020-09-05       Impact factor: 7.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.